Caris Life Sciences, Inc. 4

Director Jon Halbert received an award of 13,192 restricted stock units of Caris Life Sciences, Inc. common stock, increasing his direct holdings to 131,813 shares.

On August 14, 2026, Jon Halbert received an award of 13,192 shares of Caris Life Sciences, Inc. common stock in the form of restricted stock units that will vest in accordance with the applicable grant agreement. The transaction is coded as an acquisition (Form 4 code “A”) with no price per share reported, indicating a compensatory equity grant rather than an open‑market trade. Following this award, Halbert’s directly owned holdings increased to 131,813 shares of common stock. In addition, he is reported to have indirect beneficial ownership of 652,062 shares through a family trust and 706,531 shares through LAH Investments, Ltd., though he disclaims beneficial ownership beyond his pecuniary interest. With no market price information provided for CAI, the dollar value of both the grant and the post‑transaction holdings must be treated as not determinable from the filing alone.

Filing Facts

CIK

2019410

Ticker

CAI

Form

4

Source Type

fda

Accession

0001189394-26-000008

Alert Tier

5